Biopsy, Sentinel Lymph Node
Sentinel lymph node biopsy is a test in which a single, or sometimes several, lymph nodes are removed and assessed, usually by frozen section for metastatic malignancy. The sentinel lymph node is the first node in the lymphatic drainage of a tumor and the test is used mostly for cancer of the breast and malignant melanoma. The aim of this test is to reduce the morbidity of lymphedema following dissection of all of the nodes draining the area of a tumor (regional node dissection). In theory, if the first drainage node is negative, there is a high likelihood that the tumor has not metastasized and no further nodes need be removed, so sparing the patient lymphedema of a full regional node dissection.
It has been shown that about nine percent of patients with negative sentinel nodes have a positive node further along the nodal drainage chain (false negative), and furthermore, that about twenty percent with negative sentinel nodes will develop metastatic disease at some point. Success rate for this procedure is 90 – 95%; occasionally sentinel nodes are not found despite good localization technique. Still, the great majority of patients undergoing this procedure are spared the longterm effects of lymphedema, which include occasional cases of angiosarcoma. In breast cancer, the patient should have a diagnosis of infiltrating (invasive) breast carcinoma to qualify for this procedure. In melanoma, patients should have a diagnosis of infiltrating melanoma measuring more than 1.0 mm in thickness to qualify for SLN mapping.
Sentinel Lymph Node Biopsy is aimed at preventing the long term consequences of lymphedema due to complete regional node dissection following a diagnosis of infiltrating mammary carcinoma or infiltrating malignant melanoma. These consequences include lymphangitis, disfigurement, fungal infection, loss of range of motion and angiosarcoma.
Most common IHC markers are as follow: CD5, a transmembrane protein, Cyclin-dependent kinase inhibitor 1B (p27, Kip1), also known as CDKN1B, The combination of HMB-45, MART-1, and tyrosinase make this antibody combination a first-order pan melanoma screener, and it may prove to be a valuable marker for melanoma metastasis in sentinel lymph nodes.
- Diagnosis of infiltrating mammary carcinoma
- Diagnosis of infiltrating malignant melanoma
- As an aid in diagnosis of lymphangitis, fungal infection
- As ana aid in diagnosis of angiosarcoma
Negative lymph node by H&E light microscopy and immunohistochemistry microscopy.
Sentinel nodes are usually submitted fresh to the Pathology laboratory for frozen section, followed by paraffin embedding. Rarely no frozen is done and they are placed directly in fixative for routine processing.
- Surg Oncol Clin North Am. 1999; 8(3): 497-509. [PMID: 10448692]
- J Surg Oncol. 1998; 69(4): 212-8. [PMID: 9881937]
- Am J Surg Pathol. 1999; 23(6): 686-90. [PMID: 10366151]
- Am J Surg. 1999; 65(6): 500-5. [PMID: 10366202]